title: Iatrogenic rhinopharyngeal isolated argyria induced by silver-containing nasal drug.
abstract: Localized nasal argyria has been reported in 3 published articles as secondary to occupational exposure and involving the anterior part of the nose. No previous cases of such pathology involving the rhinopharynx were described. Here we report the first case of localized argyria of the roof and of the posterior wall of the rhinopharynx secondary to prolonged use of nasal drops containing colloidal silver protein. The recognition of such pathology can be useful to increase the number of conditions that must be considered in the differential diagnosis of rhinopharyngeal mucosa alterations.
authors.affiliation: From the *1st ENT Division, Surgical Sciences Department, and †Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Raimondo
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Garzaro
authors.forename: Luca
authors.initials: L
authors.lastname: Molinaro
authors.forename: Claudia
authors.initials: C
authors.lastname: Bartoli
authors.forename: Erica
authors.initials: E
authors.lastname: Provenzano
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Pecorari
mesh_terms: D000281:Administration, Intranasal / Q000009:adverse effects; D001129:Argyria / Q000175:diagnosis* / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D020100:Hydrogels / Q000008:administration & dosage* / Q000009:adverse effects*; D006984:Hypertrophy / Q000473:pathology; D007049:Iatrogenic Disease; D008875:Middle Aged; D009302:Nasopharyngeal Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D009305:Nasopharynx / Q000473:pathology; D018030:Silver Compounds / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D020100:Hydrogels; C500575:SilvaSorb; D018030:Silver Compounds